Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride - Wikidata - awgldk - TriplyDB

Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride

Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride

http://www.wikidata.org/entity/Q33403230

about

Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials.A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.

P2860

Q36412432-C6464189-68B9-4E44-AF6C-AFA06FB33B9D Q41537638-AC2641D0-F952-4AD8-AAD9-A6FA4C744D28

P2860

Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride

http://www.wikidata.org/entity/Q33403230

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Retrospective analysis of Japa ...... d with amrubicin hydrochloride

@ast

Retrospective analysis of Japa ...... d with amrubicin hydrochloride

@en

type

label

Retrospective analysis of Japa ...... d with amrubicin hydrochloride

@ast

Retrospective analysis of Japa ...... d with amrubicin hydrochloride

@en

prefLabel

Retrospective analysis of Japa ...... d with amrubicin hydrochloride

@ast

Retrospective analysis of Japa ...... d with amrubicin hydrochloride

@en

P1433

Q33403230-EFBB4A48-DE97-4E53-8E4B-A68CD7F120BC

P1476

Q33403230-BA3ED586-3B50-48AE-85EB-8FBDC787E208

P2093

Q33403230-1D1FAD92-E956-41D5-9DE5-27F577FF2ED2

Q33403230-2DA610EF-A72E-4013-B63D-FEA4FA0536B5

Q33403230-4FE7567C-5242-4803-96C4-5B9CDE8B32DD

Q33403230-7EF19CA8-3B75-45F3-A304-3EE4C7C191B2

Q33403230-A5AC61D3-2958-473D-9CF1-CE9735B3A8BD

Q33403230-C674E5D9-E16E-4036-B792-922FDC61F98F

P2860

Q33403230-07A8238F-190D-48B9-B005-453CA27406DA

Q33403230-267C2FA4-0148-46D6-8BF3-7949EB8AF6A6

Q33403230-3C664FF1-7646-4F4F-84AF-BF08150ECDA2

Q33403230-54C8A09D-95F1-49F3-B1C0-20EE5E8D0139

Q33403230-A7E20F94-6E05-4EDE-A9A9-B1418D5188B4

Q33403230-B4855528-C71E-4CFA-9294-AF6509240709

Q33403230-B6A8D647-3D1F-49B6-A5FB-310B7F3324FA

Q33403230-E9FCABD3-DD5D-4F46-8FB4-FA212BFE0BDA

P304

Q33403230-D7B6ABCA-B86D-4AD1-A871-26D2E06887B2

P31

Q33403230-9CF42F08-5331-4110-A461-1D16CCBCC248

P356

Q33403230-BA0DB459-46A4-4C41-A17D-29D4EE06A02C

P433

Q33403230-785E413D-6532-48B7-9A62-9C4FCBD38266

P478

Q33403230-61FBD0AC-5166-48C7-A476-D1F51F9812E4

P577

Q33403230-78DFB802-55D2-4C85-A031-4746D19C20C5

P5875

Q33403230-F5C5C701-9386-4254-A7D0-FC0B5287598B

P698

Q33403230-0D4C8B16-D51F-40F6-A198-C947A06BD3D3

P932

Q33403230-DA6BEFA9-3792-473D-A90B-35B2313F4E5F

P356

P1433

Oncology Letters

P1476

Retrospective analysis of Japa ...... d with amrubicin hydrochloride

@en

P2093

Kaoru Irisa

http://www.w3.org/2001/XMLSchema#string

Katsuhiro Masago

http://www.w3.org/2001/XMLSchema#string

Michiaki Mishima

http://www.w3.org/2001/XMLSchema#string

Tadashi Mio

http://www.w3.org/2001/XMLSchema#string

Young Hak Kim

http://www.w3.org/2001/XMLSchema#string

Yuichi Sakamori

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.

Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.

P304

569-572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL_00000101

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230830847

http://www.w3.org/2001/XMLSchema#string

P698

22966345

http://www.w3.org/2001/XMLSchema#string

P932

3436418

http://www.w3.org/2001/XMLSchema#string